Mon, 31 July 2017
Before you follow an advisor's advice on these topics, make sure you know the whole story. |
Fri, 28 July 2017
New quarterly numbers from Alphabet and Facebook sent the stocks in different directions -- why did the Street love one set of estimate-beating numbers and not the other? |
Thu, 27 July 2017
Fossil fuels may be critical today, but that fact is changing at an accelerated rate. |
Wed, 26 July 2017
Hunting for new small cap stocks to watch? We've got you covered. In today's show, we discuss how NovoCure, Flexion Therapeutics, and Zogenix want to shake-up healthcare. |
Tue, 25 July 2017
Michael Kors scoops up Jimmy Choo to keep pace with Coach, and Lululemon's back after a spring mishap, could its winning days continue? We hit these retail news items and check in on Chipotle's food-borne illness problems ahead of earnings. |
Mon, 24 July 2017
For years after the financial crisis, bank earnings fluctuated wildly due to high loan losses, volatile markets, and elevated legal expenses. Fortunately, this trend seems to have come to an end, as the results from the second quarter demonstrate.
|
Fri, 21 July 2017
Shopify and its founder Tobias Lütke have been Fool favorites for a long time -- on this episode we talk about how, despite the stock's crazy run over the past year, we're still interested in the e-commerce company. Thanks to Harry’s for supporting Motley Fool. Get your Free Trial Set – go to Harrys.com/fool |
Thu, 20 July 2017
OPEC’s production cut compliance continues to drop, is this the end of its attempt to prop up oil prices? |
Wed, 19 July 2017
After Puma Biotech's recent success, the search is on for other clinical-stage biotech stocks being run by proven CEOs. Could experience turn Aurinia Pharmaceuticals, Axovant Sciences, and Esperion Therapeutics into winners too? Thanks to Slack for supporting Motley Fool. Learn more at slack.com.
|
Tue, 18 July 2017
We field Foolish questions from the world of consumer and retail. First, Levi wants to know about the prospects for apparel retailer Buckle (and its double-digit dividend yield). Meanwhile, Shubhra is curious about Kirkland Signature and why the Costco private label is available on Amazon.com.
Thanks to Harry’s for supporting Industry Focus. Get your Free Trial Set -- go to Harrys.com/fool. |
Mon, 17 July 2017
Brian Patrick Eha, author of How Money Got Free, joins Gaby Lapera to discuss cryptocurrencies, tokens, blockchain technology, and what it all means for investors, regulators, and financial systems. Thanks to Slack for supporting Motley Fool. Learn more at slack.com. |
Fri, 14 July 2017
We love covering IPOs, but we can't bring ourselves to buy a stock that's only been publicly traded for a few months. We explain why on the final episode of "never will I ever week." |
Thu, 13 July 2017
We all make investing mistakes, but buying a commodity producer lacking a cost advantage shouldn’t be one of them. |
Wed, 12 July 2017
Only 10% of drugs make it across the FDA finish line from phase 1 clinical trials, making acquiring pre-clinical biotech stocks the riskiest game in town. |
Tue, 11 July 2017
We continue with our theme for this week, as Asit Sharma explains the major hurdles day traders and speculators face in their pursuit of easy profits. |
Mon, 10 July 2017
In this episode of Industry Focus: Financials, we dig into things we'd never do -- or, at least, that we try to avoid. This includes investing advice, as well as pointers about life more generally. |
Fri, 7 July 2017
Looking for a beach read or a podcast to pass the time on the family trip? We run through some of our favorite tech books and shows so you can still get your fix during the slow months of summer.
|
Thu, 6 July 2017
Energy: Why Exxon Mobil Paid $5.6 billion to 1 of US’s Richest Families to Expand Its Permian Shale Presence
Is being late better than never arriving for America's biggest oil major? |
Wed, 5 July 2017
After Walgreens' abandoned plans to buy it lock-stock-and-barrel, Rite Aid shares are crashing. Does this give Amazon.com the moment it's been waiting for to disrupt the prescription drug market? Thanks to Slack for supporting Motley Fool. Learn more at slack.com. |
Mon, 3 July 2017
There's no one, right answer, but getting a job while in school can help teach a lot of important things. Tune in to find out what Motley Fool contributors Dan Kline and Gaby Lapera think you ought to know. |